![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
University of Dundee Chief Scientist Office Scotland NHS Tayside |
---|---|
Information provided by: | University of Dundee |
ClinicalTrials.gov Identifier: | NCT00788749 |
This is the first randomized parallel group clinical trial looking at oral prednisolone induced medical nasal polypectomy followed by maintenance on topical steroid therapy in patients with nasal polyposis. This study also looks at the effect of aspirin sensitivity and the factors linking nasal polyps with asthma. We have also taken baseline measurements of a variety of blood, surface and biopsy markers to assess for potential to predict steroid response. Finally, the still unchartered link between nasal polyps and asthma will be explored by measuring Staphylococcal superantigens in serum before and after treatment.
Condition | Intervention | Phase |
---|---|---|
Nasal Polyps |
Drug: Prednisolone Drug: Placebo Other: fluticasone nasal drops Other: fluticasone nasal spray |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Proof Of Concept Study to Investigate the Clinical, Histological And Molecular Predictors of Response to Oral and Intranasal Corticosteroid in Nasal Polyposis |
Enrollment: | 60 |
Study Start Date: | May 2004 |
Study Completion Date: | November 2008 |
Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Placebo: Placebo Comparator
Placebo tablets for 2 weeks followed by fluticasone nasal drops 800mcg/d for 2 months followed by fluticasone nasal spray 400 mcg/d for 4 months
|
Drug: Placebo
tablets once daily
Other: fluticasone nasal drops
fluticasone nasal drops 800mcg/d
Other: fluticasone nasal spray
fluticasone nasal spray 400 mcg/d
|
Prednisolone: Experimental
25 mg Prednisolone OD for 2 weeks followed by Fluticasone nasal drops 800 mcg/d for 2 months, followed by fluticasone nasal spray 400mcg/day for 4 months
|
Drug: Prednisolone
tablets 25 mg/day
Other: fluticasone nasal drops
fluticasone nasal drops 800mcg/d
Other: fluticasone nasal spray
fluticasone nasal spray 400 mcg/d
|
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United Kingdom, Angus | |
Ninewells Hospital and Medical School | |
Dundee, Angus, United Kingdom, DD1 9SY |
Principal Investigator: | Sriram Vaidyanathan, MRCS | University of Dundee |
Study Director: | Brian J Lipworth, MD | University of Dundee |
Responsible Party: | University of Dundee ( Sriram Vaidyanathan ) |
Study ID Numbers: | GRAY07 |
Study First Received: | November 7, 2008 |
Last Updated: | November 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00788749 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
chronic rhinosinusitis nasal polyps oral steroid intranasal steroid medical polypectomy |
Pathological Conditions, Anatomical Nasal Polyps Otorhinolaryngologic Diseases Methylprednisolone Prednisolone |
Methylprednisolone acetate Fluticasone Prednisolone acetate Polyps Methylprednisolone Hemisuccinate |
Anti-Inflammatory Agents Respiratory System Agents Antineoplastic Agents, Hormonal Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Asthmatic Agents Anti-Allergic Agents Glucocorticoids |
Hormones Nose Diseases Pharmacologic Actions Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Dermatologic Agents Bronchodilator Agents |